216 related articles for article (PubMed ID: 33075426)
1. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
[TBL] [Abstract][Full Text] [Related]
2. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
[TBL] [Abstract][Full Text] [Related]
4. High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study.
Catalano R; Altieri B; Angelousi A; Arosio M; Bravi F; Canu L; Croci GA; Detomas M; Esposito E; Ferrante E; Ferrero S; Fuss CT; Kaltsas G; Kimpel O; Landwehr LS; Luconi M; Morelli V; Nesi G; Nozza E; Sbiera S; Serban AL; Ronchi CL; Mantovani G; Peverelli E
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068896
[TBL] [Abstract][Full Text] [Related]
5. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
6. IGF2 role in adrenocortical carcinoma biology.
Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
[TBL] [Abstract][Full Text] [Related]
7. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
Peixoto Lira RC; Fedatto PF; Marco Antonio DS; Leal LF; Martinelli CE; de Castro M; Tucci S; Neder L; Ramalho L; Seidinger AL; Cardinalli I; Mastellaro MJ; Yunes JA; Brandalise SR; Tone LG; Rauber Antonini SR; Scrideli CA
Endocr Relat Cancer; 2016 Jun; 23(6):481-93. PubMed ID: 27185872
[TBL] [Abstract][Full Text] [Related]
8. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
[TBL] [Abstract][Full Text] [Related]
9. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
10. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
[TBL] [Abstract][Full Text] [Related]
11. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
12. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
[TBL] [Abstract][Full Text] [Related]
13. p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells.
Sampaoli C; Cerquetti L; Gawhary RE; Bucci B; Amendola D; Marchese R; Misiti S; Novelli G; Toscano V; Stigliano A
PLoS One; 2012; 7(9):e45129. PubMed ID: 23028800
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
15. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.
Logié A; Boulle N; Gaston V; Perin L; Boudou P; Le Bouc Y; Gicquel C
J Mol Endocrinol; 1999 Aug; 23(1):23-32. PubMed ID: 10425444
[TBL] [Abstract][Full Text] [Related]
16. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
17. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
Guillaud-Bataille M; Ragazzon B; de Reyniès A; Chevalier C; Francillard I; Barreau O; Steunou V; Guillemot J; Tissier F; Rizk-Rabin M; René-Corail F; Al Ghuzlan A; Assié G; Bertagna X; Baudin E; Le Bouc Y; Bertherat J; Clauser E
PLoS One; 2014; 9(8):e103744. PubMed ID: 25089899
[TBL] [Abstract][Full Text] [Related]
18. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors.
Almeida MQ; Fragoso MC; Lotfi CF; Santos MG; Nishi MY; Costa MH; Lerario AM; Maciel CC; Mattos GE; Jorge AA; Mendonca BB; Latronico AC
J Clin Endocrinol Metab; 2008 Sep; 93(9):3524-31. PubMed ID: 18611974
[TBL] [Abstract][Full Text] [Related]
19. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.
Chimento A; Sirianni R; Casaburi I; Zolea F; Rizza P; Avena P; Malivindi R; De Luca A; Campana C; Martire E; Domanico F; Fallo F; Carpinelli G; Cerquetti L; Amendola D; Stigliano A; Pezzi V
Oncotarget; 2015 Aug; 6(22):19190-203. PubMed ID: 26131713
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
